{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:32:34Z","timestamp":1776447154130,"version":"3.51.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"1.3.5 Project for Talent Excellence Development, West China Hospital, Sichuan University","award":["No. ZYGD23035"],"award-info":[{"award-number":["No. ZYGD23035"]}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["No. 2021YFS0023"],"award-info":[{"award-number":["No. 2021YFS0023"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96710-3","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:43:59Z","timestamp":1746621839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases"],"prefix":"10.1038","volume":"15","author":[{"given":"Bofu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"96710_CR1","doi-asserted-by":"publisher","unstructured":"Soriano, J.B. et al.  Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 8, 585\u2013596. https:\/\/doi.org\/10.1016\/s2213-2600(20)30105-3 (2020).","DOI":"10.1016\/s2213-2600(20)30105-3"},{"key":"96710_CR2","doi-asserted-by":"publisher","unstructured":"Wang, H. et al. Global National life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet 388, 1459\u20131544. https:\/\/doi.org\/10.1016\/s0140-6736(16)31012-1 (2016).","DOI":"10.1016\/s0140-6736(16)31012-1"},{"key":"96710_CR3","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. Bmj 370, m3150, doi:https:\/\/doi.org\/10.1136\/bmj.m3150 (2020).","DOI":"10.1136\/bmj.m3150"},{"key":"96710_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, 47\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012 (2015).","journal-title":"J. Hepatol."},{"key":"96710_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"EASL-EASD-EASO","year":"2016","unstructured":"EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121\u20131140. https:\/\/doi.org\/10.1007\/s00125-016-3902-y (2016).","journal-title":"Diabetologia"},{"key":"96710_CR6","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/j.jhep.2023.08.003","volume":"80","author":"Q Zhao","year":"2024","unstructured":"Zhao, Q. & Deng, Y. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J. Hepatol. 80, e62\u2013e64. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.003 (2024).","journal-title":"J. Hepatol."},{"key":"96710_CR7","doi-asserted-by":"publisher","unstructured":"Younossi, Z. M. et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 76, 1423\u20131437, (2022). https:\/\/doi.org\/10.1002\/hep.32499","DOI":"10.1002\/hep.32499"},{"key":"96710_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003 (2023).","journal-title":"J. Hepatol."},{"key":"96710_CR9","doi-asserted-by":"publisher","first-page":"101497","DOI":"10.1016\/j.diabet.2023.101497","volume":"50","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A. et al. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Diabetes Metab. 50, 101497. https:\/\/doi.org\/10.1016\/j.diabet.2023.101497 (2024).","journal-title":"Diabetes Metab."},{"key":"96710_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee, H. H. et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut 73, 533\u2013540. https:\/\/doi.org\/10.1136\/gutjnl-2023-331003 (2024).","journal-title":"Gut"},{"key":"96710_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.phrs.2018.10.008","volume":"137","author":"D Visca","year":"2018","unstructured":"Visca, D., Pignatti, P., Spanevello, A., Lucini, E. & La Rocca, E. Relationship between diabetes and respiratory diseases-Clinical and therapeutic aspects. Pharmacol. Res. 137, 230\u2013235. https:\/\/doi.org\/10.1016\/j.phrs.2018.10.008 (2018).","journal-title":"Pharmacol. Res."},{"key":"96710_CR12","doi-asserted-by":"publisher","first-page":"e31710","DOI":"10.1097\/md.0000000000031710","volume":"101","author":"AR Zeina","year":"2022","unstructured":"Zeina, A. R. et al. Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study. Med. (Baltim). 101, e31710. https:\/\/doi.org\/10.1097\/md.0000000000031710 (2022).","journal-title":"Med. (Baltim)."},{"key":"96710_CR13","doi-asserted-by":"publisher","first-page":"e0262715","DOI":"10.1371\/journal.pone.0262715","volume":"17","author":"JH Roh","year":"2022","unstructured":"Roh, J. H. et al. A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults. PLoS One. 17, e0262715. https:\/\/doi.org\/10.1371\/journal.pone.0262715 (2022).","journal-title":"PLoS One"},{"key":"96710_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12916-023-03080-6","volume":"21","author":"Y Jia","year":"2023","unstructured":"Jia, Y. et al. Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: Findings from the UK biobank. BMC Med. 21, 398. https:\/\/doi.org\/10.1186\/s12916-023-03080-6 (2023).","journal-title":"BMC Med."},{"key":"96710_CR15","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"H Tilg","year":"2021","unstructured":"Tilg, H., Adolph, T. E., Dudek, M. & Knolle, P. Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat. Metab. 3, 1596\u20131607. https:\/\/doi.org\/10.1038\/s42255-021-00501-9 (2021).","journal-title":"Nat. Metab."},{"key":"96710_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1165\/rcmb.2015-0250PS","volume":"54","author":"RP Young","year":"2016","unstructured":"Young, R. P., Hopkins, R. J. & Marsland, B. The Gut-Liver-Lung axis. Modulation of the innate immune response and its possible role in chronic obstructive pulmonary disease. Am. J. Respir Cell. Mol. Biol. 54, 161\u2013169. https:\/\/doi.org\/10.1165\/rcmb.2015-0250PS (2016).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"96710_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384. https:\/\/doi.org\/10.1002\/hep.28431 (2016).","journal-title":"Hepatology"},{"key":"96710_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000148","author":"MJ Miller","year":"2023","unstructured":"Miller, M. J. et al. Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age. Hepatol. Commun. 7 https:\/\/doi.org\/10.1097\/hc9.0000000000000148 (2023).","journal-title":"Hepatol.Commun."},{"key":"96710_CR19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40618-022-01766-x","volume":"45","author":"K Pafili","year":"2022","unstructured":"Pafili, K. et al. Non-alcoholic fatty liver disease through the female lifespan: The role of sex hormones. J. Endocrinol. Invest. 45, 1609\u20131623. https:\/\/doi.org\/10.1007\/s40618-022-01766-x (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"96710_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/hep.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi, O. et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology 78, 272\u2013283. https:\/\/doi.org\/10.1097\/hep.0000000000000329 (2023).","journal-title":"Hepatology"},{"key":"96710_CR21","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha, J., Yim, S. Y. & Karagozian, R. Mortality and liver-Related events in lean versus Non-Lean nonalcoholic fatty liver disease: A systematic review and Meta-analysis. Clin. Gastroenterol. Hepatol. 21, 2496\u20132507e2495. https:\/\/doi.org\/10.1016\/j.cgh.2022.11.019 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"96710_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s12072-024-10716-z","volume":"18","author":"M Souza","year":"2024","unstructured":"Souza, M., Diaz, I. & Al-Sharif, L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol. Int. 18, 1396\u20131415. https:\/\/doi.org\/10.1007\/s12072-024-10716-z (2024).","journal-title":"Hepatol. Int."},{"key":"96710_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/liv.15763","volume":"44","author":"M Souza","year":"2024","unstructured":"Souza, M., Diaz, I., Barchetta, I. & Mantovani, A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Liver Int. 44, 6\u201314. https:\/\/doi.org\/10.1111\/liv.15763 (2024).","journal-title":"Liver Int."},{"key":"96710_CR24","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.aohep.2024.101288","volume":"29","author":"W Wongtrakul","year":"2024","unstructured":"Wongtrakul, W., Charatcharoenwitthaya, N. & Charatcharoenwitthaya, P. Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: an updated meta-analysis. Ann. Hepatol. 29, 101288. https:\/\/doi.org\/10.1016\/j.aohep.2024.101288 (2024).","journal-title":"Ann. Hepatol."},{"key":"96710_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-3-319-48382-5_14","volume":"960","author":"AB Engin","year":"2017","unstructured":"Engin, A. B. Adipocyte-Macrophage Cross-Talk in obesity. Adv. Exp. Med. Biol. 960, 327\u2013343. https:\/\/doi.org\/10.1007\/978-3-319-48382-5_14 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"96710_CR26","doi-asserted-by":"publisher","first-page":"100692","DOI":"10.1016\/j.jhepr.2023.100692","volume":"5","author":"M Zheng","year":"2023","unstructured":"Zheng, M. et al. Genomic analysis of lean individuals with NAFLD identifies Monogenic disorders in a prospective cohort study. JHEP Rep. 5, 100692. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100692 (2023).","journal-title":"JHEP Rep."},{"key":"96710_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12072-022-10304-z","volume":"16","author":"D Chahal","year":"2022","unstructured":"Chahal, D. et al. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK biobank. Hepatol. Int. 16, 325\u2013336. https:\/\/doi.org\/10.1007\/s12072-022-10304-z (2022).","journal-title":"Hepatol. Int."},{"key":"96710_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.numecd.2023.11.004","volume":"34","author":"Y Jia","year":"2024","unstructured":"Jia, Y. et al. Association between metabolic dysfunction-associated fatty liver disease and abdominal aortic aneurysm. Nutr. Metab. Cardiovasc. Dis. 34, 953\u2013962. https:\/\/doi.org\/10.1016\/j.numecd.2023.11.004 (2024).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"96710_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/s-0035-1562947","volume":"35","author":"QM Anstee","year":"2015","unstructured":"Anstee, Q. M. & Day, C. P. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 35, 270\u2013290. https:\/\/doi.org\/10.1055\/s-0035-1562947 (2015).","journal-title":"Semin Liver Dis."},{"key":"96710_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J. Hepatol. 68, 268\u2013279. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003 (2018).","journal-title":"J. Hepatol."},{"key":"96710_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/life13010036","author":"B Gjura\u0161in","year":"2022","unstructured":"Gjura\u0161in, B., Jeli\u010di\u0107, M., Kutle\u0161a, M. & Papi\u0107, N. The impact of nonalcoholic fatty liver disease on severe Community-Acquired pneumonia outcomes. Life (Basel).  https:\/\/doi.org\/10.3390\/life13010036 (2022).","journal-title":"Life(Basel)"},{"key":"96710_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112978","author":"S Kotlyarov","year":"2021","unstructured":"Kotlyarov, S. & Bulgakov, A. Lipid metabolism disorders in the comorbid course of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease. Cells 10 https:\/\/doi.org\/10.3390\/cells10112978 (2021).","journal-title":"Cells"},{"key":"96710_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1165\/rcmb.2014-0195OC","volume":"53","author":"KL Hilliard","year":"2015","unstructured":"Hilliard, K. L. et al. The Lung-Liver axis: A requirement for maximal innate immunity and hepatoprotection during pneumonia. Am. J. Respir Cell. Mol. Biol. 53, 378\u2013390. https:\/\/doi.org\/10.1165\/rcmb.2014-0195OC (2015).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"96710_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1165\/rcmb.2016-0052PS","volume":"54","author":"SA Shore","year":"2016","unstructured":"Shore, S. A. & Cho, Y. Obesity and asthma: Microbiome-metabolome interactions. Am. J. Respir Cell. Mol. Biol. 54, 609\u2013617. https:\/\/doi.org\/10.1165\/rcmb.2016-0052PS (2016).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"96710_CR35","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.mam.2021.100973","volume":"82","author":"H Qian","year":"2021","unstructured":"Qian, H. et al. Autophagy in liver diseases: A review. Mol. Aspects Med. 82, 100973. https:\/\/doi.org\/10.1016\/j.mam.2021.100973 (2021).","journal-title":"Mol. Aspects Med."},{"key":"96710_CR36","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry, A. et al. Comparison of sociodemographic and Health-Related characteristics of UK biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026\u20131034. https:\/\/doi.org\/10.1093\/aje\/kwx246 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"96710_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-6-33","author":"G Bedogni","year":"2006","unstructured":"Bedogni, G. et al. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6 https:\/\/doi.org\/10.1186\/1471-230x-6-33 (2006).","journal-title":"BMCGastroenterol."},{"key":"96710_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/dme.13565","volume":"35","author":"AL Sberna","year":"2018","unstructured":"Sberna, A. L. et al. European association for the study of the liver (EASL), European association for the study of diabetes (EASD) and European association for the study of obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with type 2 diabetes. Diabet. Med. 35, 368\u2013375. https:\/\/doi.org\/10.1111\/dme.13565 (2018).","journal-title":"Diabet. Med."},{"key":"96710_CR39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854. https:\/\/doi.org\/10.1002\/hep.21496 (2007).","journal-title":"Hepatology"},{"key":"96710_CR40","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina, R. M. et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219\u20131230e1216. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.032 (2016).","journal-title":"Gastroenterology"},{"key":"96710_CR41","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1111\/liv.15706","volume":"43","author":"A Caddeo","year":"2023","unstructured":"Caddeo, A., Spagnuolo, R. & Maurotti, S. MBOAT7 in liver and extrahepatic diseases. Liver Int. 43, 2351\u20132364. https:\/\/doi.org\/10.1111\/liv.15706 (2023).","journal-title":"Liver Int."},{"key":"96710_CR42","doi-asserted-by":"publisher","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes, E. K. et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324. https:\/\/doi.org\/10.1371\/journal.pgen.1001324 (2011).","journal-title":"PLoS Genet."},{"key":"96710_CR43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"N Santoro","year":"2012","unstructured":"Santoro, N. et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55, 781\u2013789. https:\/\/doi.org\/10.1002\/hep.24806 (2012).","journal-title":"Hepatology"},{"key":"96710_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352\u2013356. https:\/\/doi.org\/10.1038\/ng.2901 (2014).","journal-title":"Nat. Genet."},{"key":"96710_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gtc.2019.09.001","volume":"49","author":"J Kozlitina","year":"2020","unstructured":"Kozlitina, J. Genetic risk factors and disease modifiers of nonalcoholic steatohepatitis. Gastroenterol. Clin. North. Am. 49, 25\u201344. https:\/\/doi.org\/10.1016\/j.gtc.2019.09.001 (2020).","journal-title":"Gastroenterol. Clin. North. Am."},{"key":"96710_CR46","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461\u20131465. https:\/\/doi.org\/10.1038\/ng.257 (2008).","journal-title":"Nat. Genet."},{"key":"96710_CR47","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","volume":"158","author":"M Krawczyk","year":"2020","unstructured":"Krawczyk, M., Liebe, R. & Lammert, F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 158, 1865\u20131880e1861. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.053 (2020).","journal-title":"Gastroenterology"},{"key":"96710_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/pubmed\/fdr054","volume":"34","author":"EM Burns","year":"2012","unstructured":"Burns, E. M. et al. Systematic review of discharge coding accuracy. J. Public. Health (Oxf). 34, 138\u2013148. https:\/\/doi.org\/10.1093\/pubmed\/fdr054 (2012).","journal-title":"J. Public. Health (Oxf)"},{"key":"96710_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/resp.14186","volume":"27","author":"N Horita","year":"2022","unstructured":"Horita, N. et al. Decline in mortality due to respiratory diseases in Japan during the coronavirus disease 2019 pandemic. Respirology 27, 175\u2013176. https:\/\/doi.org\/10.1111\/resp.14186 (2022).","journal-title":"Respirology"},{"key":"96710_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1136\/thorax-2023-220703","volume":"79","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Predictive value of lung function measures for cardiovascular risk: A large prospective cohort study. Thorax 79, 250\u2013258. https:\/\/doi.org\/10.1136\/thorax-2023-220703 (2024).","journal-title":"Thorax"},{"key":"96710_CR51","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/s0140-6736(12)60404-8","volume":"379","author":"R Collins","year":"2012","unstructured":"Collins, R. What makes UK biobank special? Lancet 379, 1173\u20131174. https:\/\/doi.org\/10.1016\/s0140-6736(12)60404-8 (2012).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96710-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96710-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96710-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:44:00Z","timestamp":1746621840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96710-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96710"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96710-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the UK Biobank study was obtained from the NHS National Research Ethics Service (16\/NW\/0274). The experimental protocols were established according to the ethical guidelines of the Helsinki Declaration. Written informed consent was obtained from the participants or their guardians. All methods were carried out in accordance with guidelines and regulations developed by the UK Biobank. The use of the data was approved by the Human Ethical Committee of the West China Hospital of Sichuan University (2023\u2009\u2212\u20091829).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15937"}}